Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

162 281

Changes in operating assets and liabilities:

Other assets 66 105

Accounts payable and accrued liabilities (1,557) 1,072

Deferred rent 1,452 1,443

Net cash used in operating activities (37,651) (32,105)

Investing activities:

Purchases of property and equipment (9,571) (8,586)

Purchases of short-term investments (14,899) (63,386)

Maturities of short-term investments 39,898 58,348

Restricted cash - (1,901)

Net cash provided by (used in) investing

activities 15,428 (15,525)

Financing activities:

Proceeds from debt 6,884 7,563

Payments on debt (6,092) (3,113)

Issuance of common stock and warrants 33,546 45,369

Repurchase of restricted common stock (2) (5)

Net cash provided by financing activities 34,336 49,814

Net increase in cash and cash equivalents 12,113 2,184

Cash and cash equivalents at beginning

of period 14,249 12,065

Cash and cash equivalents at end of period $26,362 $14,249

Supplemental disclosures of cash flow

information:

Cash paid for interest $1,363 $703

Supplemental non-cash activities:

Capitalized interest recorded as property,

plant and equipment $404 $91

Accrued asset acquisitions $(1,670) $1,819

Leasehold improvements acquired
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015   Inocucor Technologies Inc ., the ... for farmers, has received a notice of allowance ... its patent application to protect Inocucor consortia and ... enhance yields on farms and in greenhouses. ... IN-M1 microbial consortium and its fermentation byproducts, which ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® ... Monday. The venture will bring the world’s most efficient gas dissolution technology to ... and technologies to both the industrial and municipal markets. With offices located in ...
(Date:7/27/2015)... July 27, 2015 The Brain ... winners of its annual Klerman and Freedman Prizes, ... who have been supported by NARSAD Young Investigator ... pursue innovative ideas in neurobiological and psychosocial research, ... for the early detection, treatment, prevention and cure ...
(Date:7/27/2015)... -- IDEXX Laboratories, Inc. (NASDAQ: IDXX ) announced ... 100,000 specimens to IDEXX Reference Laboratories for symmetric dimethylarginine, ... since the breakthrough kidney function test launched in the ... of suffering and death in cats and dogs. The ... accepted kidney disease prevalence data showing that 1 in ...
Breaking Biology Technology:Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... LLC (, http://www.CJPS-Enterprises.com ) announced that it ... services to leverage companies, intellectual property (IP) to ... of their intangible assets.,This customized service is execution-driven, ... a firm that specializes in growing,companies in the ...
... ... Prostate Surgery, SAN DIEGO, Nov. ... InnerCool Therapies, Inc., today,announced that it has developed a pelvic cooling ... surgery,for prostate cancer (radical prostatectomy). The new technology is being,applied in ...
... Vitamin E May Help,Prevent, Cardiovascular Events in Hp2-2 ... (Amex: SYI ) today announced new data demonstrating ... Diabetes may result,in an increased risk of heart attack ... today at the Annual Scientific,Sessions of the American Heart ...
Cached Biology Technology:CJPS Enterprises Provides New Strategies To Create Additional Revenues for Companies with Intellectual Property 2Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 2Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 3Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 4Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 5Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 6Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 7Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 8Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 2Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 3Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 4
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... Mount Sinai School of Medicine have found in a ... Mount Sinai stabilized or improved cardiac function in people ... of the therapy, called SERCA2a, experienced substantial clinical benefit ... need in this population. The data are published online ...
... Some areas of the southern United States are suffering from ... University study shows that could prove problematic for aquatic organisms. ... some chemicals in the environment more toxic to fish and ... exacerbate the magnitudes of the natural pH shifts in the ...
... seawater algae could hold the key to crops as a ... climates. Researchers at the University of Edinburgh have found ... its main food source is in short supply. Understanding ... when nutrients are scarce and to grow high-yield plants for ...
Cached Biology News:Mount Sinai researchers develop new gene therapy for heart failure 2Study shows climate change makes some chemicals more toxic to aquatic life 2
... The dual-bay DNA Engine Dyad ... for DNA amplification (PCR). The chassis ... units (sample-holder, heat-pump assemblies), which hold ... Color display offers graphical programming with ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
... Disruption of the mitochondrial transmembrane ... intracellular events that occur following induction ... Detection Kit utilizes a lipophilic cation, ... activity marker. MitoLight is a mitochondrial ...
Biology Products: